First Wave BioPharma to Participate in ”Fireside Chat” at the 34th Annual Roth Conference
08 mars 2022 07h00 HE
|
First Wave BioPharma, Inc.
BOCA RATON, Fla., March 08, 2022 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ:FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in...
First Wave BioPharma to Participate in the 2022 BIO CEO & Investor Conference
07 févr. 2022 07h30 HE
|
First Wave BioPharma, Inc.
BOCA RATON, Fla., Feb. 07, 2022 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ:FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in...
First Wave BioPharma Completes Enrollment for Part 2 of RESERVOIR Phase 2 Trial Evaluating FW-COV in COVID-19-Related GI Infections
06 janv. 2022 07h00 HE
|
First Wave BioPharma, Inc.
No Drug-Related SAEs Reported; Topline Data Expected 1H 2022 Part 2 of RESERVOIR Trial to Evaluate Efficacy of FW-COV, an Oral Formulation of Niclosamide, and Expand Safety Observations on...
First Wave BioPharma to Participate in Two Investor Conferences in January 2022
04 janv. 2022 07h00 HE
|
First Wave BioPharma, Inc.
BOCA RATON, Fla., Jan. 04, 2022 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ:FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in...
First Wave BioPharma Chairman and CEO Issues Letter to Shareholders
13 déc. 2021 07h00 HE
|
First Wave BioPharma, Inc.
BOCA RATON, Fla., Dec. 13, 2021 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ:FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in...
First Wave BioPharma Names Brian Feagan, M.D., to Scientific Advisory Board
09 déc. 2021 07h00 HE
|
First Wave BioPharma, Inc.
BOCA RATON, Fla., Dec. 09, 2021 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ:FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in...
First Wave BioPharma’s CEO and President, James Sapirstein, to Participate in CEO Panel Discussion at 2021 BioFlorida Conference
06 déc. 2021 07h00 HE
|
First Wave BioPharma, Inc.
BOCA RATON, Fla., Dec. 06, 2021 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ:FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in...
First Wave BioPharma Announces Independent Data Monitoring Committee Provides Positive Interim Safety Assessment for Part 2 COVID-19 RESERVOIR Clinical Trial of Niclosamide for the Treatment of Gastrointestinal Infections
30 nov. 2021 07h00 HE
|
First Wave BioPharma, Inc.
BOCA RATON, Fla., Nov. 30, 2021 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ:FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in...
AzurRx BioPharma CEO Issues Letter to Shareholders Regarding Recent Acquisition of First Wave Bio and Creation of First Wave BioPharma
14 sept. 2021 07h30 HE
|
AzurRx BioPharma, Inc.
BOCA RATON, Fla., Sept. 14, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ:AZRX), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the...
AzurRx BioPharma Announces $3.0 Million Bought Deal Offering of Common Stock
22 juil. 2021 16h51 HE
|
AzurRx BioPharma, Inc.
BOCA RATON, Fla., July 22, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ: AZRX), (“AzurRx” or the “Company”), a clinical stage biopharmaceutical company specializing in the development of...